Pursuing the Goal of a Donor for Everyone in Need
Mené sur 551 patients traités entre 2004 et 2009 pour une leucémie à haut risque dans 48 centres hospitaliers, cet essai de phase III compare, du point de vue du taux de survie à 2 ans, une greffe de cellules souches du sang périphérique et une greffe de moelle osseuse provenant de donneurs non apparentés (durée médiane de suivi des patients survivants: 36 mois)
Allogeneic hematopoietic stem-cell transplantation can be a lifesaving treatment for many patients with hematologic cancers. However, less than 30% of patients have an HLA-matched family member to serve as a donor, and with the shrinking size of the average family in the United States, this percentage is expected to drop. The first successful unrelated-donor transplantation for leukemia was performed in 1979, after Robert Graves contacted Dr. John Hansen at the Fred Hutchinson Cancer Research Center and asked whether a matched unrelated donor could be identified for his 10-year-old daughter, who had acute lymphocytic leukemia. Mr. Graves knew there was no . . .
New England Journal of Medicine , éditorial, 2011